Abstract

Genotyping of thiopurine S-methyltransferase (TPMT) is recommended for predicting the adverse drug response of thiopurines. In the current study, a novel version of allele-specific PCR (AS-PCR), termed competitive real-time fluorescent AS-PCR (CRAS-PCR) was developed to analyze the TPMT*2 genotype in ethnic Chinese. This technique simultaneously uses wild-type and mutant allele-specific scorpion primers in a single reaction. To determine the optimal conditions for both traditional AS-PCR and CRAS-PCR, we used the Taguchi method, an engineering optimization process that balances the concentrations of all components using an orthogonal array rather than a factorial array. Instead of running up to 264 experiments with the conventional factorial method, the Taguchi method achieved the same optimization using only 16 experiments. The optimized CRAS-PCR system completely avoided non-specific amplification occurring in traditional AS-PCR and could be performed at much more relaxed reaction conditions at 1% sensitivity, similar to traditional AS-PCR. TPMT*2 genotyping of 240 clinical samples was consistent with published data. In conclusion, CRAS-PCR is a novel and robust genotyping method, and the Taguchi method is an effective tool for the optimization of molecular analysis techniques.

Highlights

  • Since their invention [1], thiopurine drugs, including azathioprine (AZA), 6-mercaptopurine (6MP), and 6-thioguanine (6TG), have significantly advanced the treatment of hematologic malignancies, organ transplantation, inflammatory bowel disease (IBD) and some autoimmune diseases [2]

  • In which unidirectional WT- and MT-AS primers (WT-ASF and mutant allele-specific forward (MT-ASF) in the present study) are used in a single tube to eliminate the non-specific amplification commonly occurring in traditional allele-specific PCR (AS-PCR)

  • In the AS-PCR system, a defined AS primer has only a single base at its 39-end that distinguishes the genotype of the input DNA [10,12,13,19,20]

Read more

Summary

Introduction

Since their invention [1], thiopurine drugs, including azathioprine (AZA), 6-mercaptopurine (6MP), and 6-thioguanine (6TG), have significantly advanced the treatment of hematologic malignancies, organ transplantation, inflammatory bowel disease (IBD) and some autoimmune diseases (e.g., rheumatoid arthritis, autoimmune hepatitis) [2]. Since the initial identification of SNPs in TPMT, more than 30 mutant alleles of the gene have been identified, of which TPMT*2, *3A, *3B, *3C, and *4 are the most common [1,2,3,4,5]. About 3–14% of patients have a heterozygous TPMT genotype with one variant TMPT allele [1,2,3,4,5]. Independent and professional groups have recommended analyzing the TPMT genotype status to determine thiopurine drug dosing [5,6,7,8,9]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends that the initial dosage of AZA or 6-MP be reduced by 30–70% for patients who possess heterozygous genotypes of TPMT*2, *3A, *3C, or *4 [6,7]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.